252 related articles for article (PubMed ID: 33093161)
1. Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review.
Liss MA; Leach RJ; Sanda MG; Semmes OJ
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2454-2462. PubMed ID: 33093161
[TBL] [Abstract][Full Text] [Related]
2. Systematic, evidence-based discovery of biomarkers at the NCI.
Prensner JR; Chinnaiyan AM; Srivastava S
Clin Exp Metastasis; 2012 Oct; 29(7):645-52. PubMed ID: 22868876
[TBL] [Abstract][Full Text] [Related]
3. Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis.
Troyer DA; Mubiru J; Leach RJ; Naylor SL
Dis Markers; 2004; 20(2):117-28. PubMed ID: 15322319
[TBL] [Abstract][Full Text] [Related]
4. Molecular Biomarkers in the Clinical Management of Prostate Cancer.
Udager AM; Tomlins SA
Cold Spring Harb Perspect Med; 2018 Nov; 8(11):. PubMed ID: 29311125
[TBL] [Abstract][Full Text] [Related]
5. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
6. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.
Williams SB; Salami S; Regan MM; Ankerst DP; Wei JT; Rubin MA; Thompson IM; Sanda MG
Cancer; 2012 May; 118(10):2651-8. PubMed ID: 22006057
[TBL] [Abstract][Full Text] [Related]
7. Recent progress and perspectives on prostate cancer biomarkers.
Hatakeyama S; Yoneyama T; Tobisawa Y; Ohyama C
Int J Clin Oncol; 2017 Apr; 22(2):214-221. PubMed ID: 27730440
[TBL] [Abstract][Full Text] [Related]
8. The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers.
Srivastava S; Wagner PD
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2401-2410. PubMed ID: 32357955
[TBL] [Abstract][Full Text] [Related]
9. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
Sokoll LJ; Wang Y; Feng Z; Kagan J; Partin AW; Sanda MG; Thompson IM; Chan DW
J Urol; 2008 Aug; 180(2):539-43; discussion 543. PubMed ID: 18550118
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation.
Farooq M; Herman JG
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2416-2422. PubMed ID: 33148791
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
Lieberman R
Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation.
Bresalier RS; Grady WM; Markowitz SD; Nielsen HJ; Batra SK; Lampe PD
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2431-2440. PubMed ID: 32299850
[TBL] [Abstract][Full Text] [Related]
13. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
14. A favorable view: progress in cancer prevention and screening.
Greenwald P
Recent Results Cancer Res; 2007; 174():3-17. PubMed ID: 17302181
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
Black A; Berg CD
Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
[TBL] [Abstract][Full Text] [Related]
16. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
17. Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey.
Leyva B; Persoskie A; Ottenbacher A; Hamilton JG; Allen JD; Kobrin SC; Taplin SH
J Cancer Educ; 2016 Dec; 31(4):693-701. PubMed ID: 26498649
[TBL] [Abstract][Full Text] [Related]
18. A survey of patient advocates within the National Cancer Institute's Prostate Cancer SPORE Program: who are they? what motivates them? what might they tell us?
Kovtun IV; Engh J; Jatoi A
J Cancer Educ; 2008; 23(4):222-5. PubMed ID: 19058069
[TBL] [Abstract][Full Text] [Related]
19. Overdiagnosis and overtreatment of prostate cancer.
Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
[TBL] [Abstract][Full Text] [Related]
20. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
